000875374 001__ 875374
000875374 005__ 20210130004924.0
000875374 0247_ $$2doi$$a10.1136/jnnp-2019-322614
000875374 0247_ $$2ISSN$$a0022-3050
000875374 0247_ $$2ISSN$$a0266-8637
000875374 0247_ $$2ISSN$$a0368-329X
000875374 0247_ $$2ISSN$$a1468-330X
000875374 0247_ $$2Handle$$a2128/25316
000875374 0247_ $$2altmetric$$aaltmetric:81449598
000875374 0247_ $$2pmid$$apmid:32371534
000875374 0247_ $$2WOS$$aWOS:000545962100005
000875374 037__ $$aFZJ-2020-01988
000875374 082__ $$a610
000875374 1001_ $$00000-0003-0477-2289$$aJost, Stefanie Theresa$$b0$$eCorresponding author
000875374 245__ $$aA prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson’s disease: results at the 36-month follow-up
000875374 260__ $$aLondon$$bBMJ Publishing Group$$c2020
000875374 3367_ $$2DRIVER$$aarticle
000875374 3367_ $$2DataCite$$aOutput Types/Journal article
000875374 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1595006828_26338
000875374 3367_ $$2BibTeX$$aARTICLE
000875374 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000875374 3367_ $$00$$2EndNote$$aJournal Article
000875374 520__ $$aObjective To examine 36-month effects of bilateral subthalamic nucleus deep brain stimulation (STN-DBS) on non-motor symptoms (NMS) compared with standard-of-care medical treatment (MED) in Parkinson’s disease (PD).Methods Here we report the 36-month follow-up of a prospective, observational, controlled, international multicentre study of the NILS cohort. Assessments included NMSScale (NMSS), PDQuestionnaire-8 (PDQ-8), Scales for Outcomes in PD (SCOPA)-motor examination, -activities of daily living, and -complications, and levodopa equivalent daily dose (LEDD). Propensity score matching resulted in a pseudo-randomised sub-cohort balancing baseline demographic and clinical characteristics between the STN-DBS and MED groups. Within-group longitudinal outcome changes were analysed using Wilcoxon signed-rank and between-group differences of change scores with Mann-Whitney U test. Strength of clinical responses was quantified with Cohen’s effect size. In addition, bivariate correlations of change scores were explored.Results Propensity score matching applied on the cohort of 151 patients (STN-DBS n=67, MED n=84) resulted in a well-balanced sub-cohort including 38 patients per group. After 36 months, STN-DBS significantly improved NMSS, PDQ-8, SCOPA-motor examination and -complications and reduced LEDD. Significant between-group differences, all favouring STN-DBS, were found for NMSS, SCOPA-motor complications, LEDD (large effects), motor examination and PDQ-8 (moderate effects). Furthermore, significant differences were found for the sleep/fatigue, urinary (large effects) and miscellaneous NMSS domains (moderate effects). NMSS total and PDQ-8 change scores correlated significantly.Conclusions This study provides Class IIb evidence for beneficial effects of STN-DBS on NMS at 36-month follow-up which also correlated with quality of life improvements. This highlights the importance of NMS for DBS outcomes assessments.
000875374 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000875374 588__ $$aDataset connected to CrossRef
000875374 7001_ $$0P:(DE-HGF)0$$aSauerbier, Anna$$b1
000875374 7001_ $$0P:(DE-HGF)0$$aVisser-Vandewalle, Veerle$$b2
000875374 7001_ $$0P:(DE-HGF)0$$aAshkan, Keyoumars$$b3
000875374 7001_ $$0P:(DE-HGF)0$$aSilverdale, Monty$$b4
000875374 7001_ $$0P:(DE-HGF)0$$aEvans, Julian$$b5
000875374 7001_ $$0P:(DE-HGF)0$$aLoehrer, Philipp A$$b6
000875374 7001_ $$0P:(DE-HGF)0$$aRizos, Alexandra$$b7
000875374 7001_ $$0P:(DE-HGF)0$$aPetry-Schmelzer, Jan Niklas$$b8
000875374 7001_ $$0P:(DE-HGF)0$$aReker, Paul$$b9
000875374 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon Rudolf$$b10
000875374 7001_ $$0P:(DE-HGF)0$$aFranklin, Jeremy$$b11
000875374 7001_ $$0P:(DE-HGF)0$$aSamuel, Michael$$b12
000875374 7001_ $$0P:(DE-HGF)0$$aSchnitzler, Alfons$$b13
000875374 7001_ $$0P:(DE-Juel1)131613$$aBarbe, Michael Thomas$$b14
000875374 7001_ $$0P:(DE-HGF)0$$aAntonini, Angelo$$b15
000875374 7001_ $$0P:(DE-HGF)0$$aMartinez-Martin, Pablo$$b16
000875374 7001_ $$0P:(DE-HGF)0$$aTimmermann, Lars$$b17
000875374 7001_ $$0P:(DE-HGF)0$$aRay-Chaudhuri, K.$$b18
000875374 7001_ $$00000-0001-8849-4233$$aDafsari, Haidar S$$b19$$eCorresponding author
000875374 773__ $$0PERI:(DE-600)1480429-3$$a10.1136/jnnp-2019-322614$$gp. jnnp-2019-322614 -$$n7$$p687-694$$tJournal of neurology, neurosurgery, and psychiatry$$v91$$x1468-330X$$y2020
000875374 8564_ $$uhttps://juser.fz-juelich.de/record/875374/files/Jost_2020_J%20Neurol%20Neurosurg%20Psychiatry_A%20prospective%2C%20controlled%20study%20of%20non-motor%20effects%20of%20subthalamic%20stimulation%20in%20Parkinson%E2%80%99s%20disease-1.pdf$$yRestricted
000875374 8564_ $$uhttps://juser.fz-juelich.de/record/875374/files/Jost_2020_Post%20Print_Neurosurgery%20and%20Psychiatry_A%20prospective%2C%20controlled%20study%20of%20non%20motor%20effects%20of%20subthalamic%20stimulation%20in%20Parkinsons%20disease.pdf$$yOpenAccess
000875374 8564_ $$uhttps://juser.fz-juelich.de/record/875374/files/Jost_2020_J%20Neurol%20Neurosurg%20Psychiatry_A%20prospective%2C%20controlled%20study%20of%20non-motor%20effects%20of%20subthalamic%20stimulation%20in%20Parkinson%E2%80%99s%20disease-1.pdf?subformat=pdfa$$xpdfa$$yRestricted
000875374 8564_ $$uhttps://juser.fz-juelich.de/record/875374/files/Jost_2020_Post%20Print_Neurosurgery%20and%20Psychiatry_A%20prospective%2C%20controlled%20study%20of%20non%20motor%20effects%20of%20subthalamic%20stimulation%20in%20Parkinsons%20disease.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000875374 909CO $$ooai:juser.fz-juelich.de:875374$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000875374 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b10$$kFZJ
000875374 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000875374 9141_ $$y2020
000875374 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000875374 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000875374 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000875374 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL NEUROSUR PS : 2017
000875374 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL NEUROSUR PS : 2017
000875374 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000875374 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000875374 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000875374 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000875374 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000875374 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000875374 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000875374 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000875374 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000875374 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000875374 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000875374 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000875374 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000875374 920__ $$lyes
000875374 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000875374 980__ $$ajournal
000875374 980__ $$aVDB
000875374 980__ $$aUNRESTRICTED
000875374 980__ $$aI:(DE-Juel1)INM-3-20090406
000875374 9801_ $$aFullTexts